BRPI0513858A - compostos de benziltriazolona como inibidores não-nucleosìdeos da transcriptase reversa - Google Patents

compostos de benziltriazolona como inibidores não-nucleosìdeos da transcriptase reversa

Info

Publication number
BRPI0513858A
BRPI0513858A BRPI0513858-2A BRPI0513858A BRPI0513858A BR PI0513858 A BRPI0513858 A BR PI0513858A BR PI0513858 A BRPI0513858 A BR PI0513858A BR PI0513858 A BRPI0513858 A BR PI0513858A
Authority
BR
Brazil
Prior art keywords
benzyltriazolone
compounds
reverse transcriptase
transcriptase inhibitors
nucleoside reverse
Prior art date
Application number
BRPI0513858-2A
Other languages
English (en)
Inventor
James Patrick Dunn
Todd Richard Elworthy
Dimitrios Stefanidis
Zachary Kevin Sweeney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0513858A publication Critical patent/BRPI0513858A/pt
Publication of BRPI0513858B1 publication Critical patent/BRPI0513858B1/pt
Publication of BRPI0513858B8 publication Critical patent/BRPI0513858B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

COMPOSTOS DE BENZILTRIAZOLONA COMO INIBIDORES NãO-NUCLEOSìDEOS DA TRANSCRIPTASE REVERSA. A presente invenção refere-se a um composto de acordo com a fórmula (I), aos métodos para tratar as doenças mediadas pelo vírus da imunodeficiência humana por administração de um composto de acordo com a fórmula (I) e às composições farmacêuticas para tratar as doenças mediadas pelo vírus da imunodeficiência humana, contendo um composto de acordo com a fórmula, onde R¬ 1¬, R¬ 2¬, R¬ 3¬, R¬ 4¬ R¬ 5¬ são como definidos aqui.
BRPI0513858A 2004-07-27 2005-07-20 compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende BRPI0513858B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59131104P 2004-07-27 2004-07-27
US60/591,311 2004-07-27
PCT/EP2005/007893 WO2006010545A1 (en) 2004-07-27 2005-07-20 Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors

Publications (3)

Publication Number Publication Date
BRPI0513858A true BRPI0513858A (pt) 2008-05-20
BRPI0513858B1 BRPI0513858B1 (pt) 2020-11-10
BRPI0513858B8 BRPI0513858B8 (pt) 2021-05-25

Family

ID=35056908

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513858A BRPI0513858B8 (pt) 2004-07-27 2005-07-20 compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende

Country Status (16)

Country Link
US (1) US7666891B2 (pt)
EP (1) EP1773790B1 (pt)
JP (1) JP4675959B2 (pt)
CN (1) CN1993332B (pt)
AR (1) AR050266A1 (pt)
AU (1) AU2005266530B2 (pt)
BR (1) BRPI0513858B8 (pt)
CA (1) CA2574308C (pt)
ES (1) ES2391461T3 (pt)
IL (1) IL180495A (pt)
MX (1) MX2007000788A (pt)
NO (1) NO338376B1 (pt)
RU (1) RU2394028C2 (pt)
SG (1) SG148179A1 (pt)
TW (1) TWI299334B (pt)
WO (1) WO2006010545A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
BRPI0617720A2 (pt) 2005-10-19 2011-08-02 Hoffmann La Roche compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
WO2008019968A1 (en) * 2006-08-16 2008-02-21 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
CA2682637A1 (en) * 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
BRPI0810496A2 (pt) * 2007-04-09 2018-11-06 Hoffmann La Roche inibidores de transcriptase reversa de não-nucleosídeo
CN101679320B (zh) * 2007-05-30 2013-01-23 弗·哈夫曼-拉罗切有限公司 制备三唑酮的方法
EP2155692B1 (en) * 2007-05-30 2015-06-17 F. Hoffmann-La Roche AG Non-nucleoside reverse transcriptase inhibitors
MX2009013865A (es) * 2007-06-22 2010-01-27 Hoffmann La Roche Urea y derivados carbamato como inhibidores no nucleosidicos de la transcriptasa inversa.
MX2010006397A (es) 2007-12-21 2010-07-05 Hoffmann La Roche Compuestos heterociclicos antivirales.
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
CN101723909B (zh) * 2008-10-29 2011-12-28 天津药物研究院 三唑酮类化合物、其制备方法和用途
CN101735023B (zh) * 2008-11-24 2014-07-09 联化科技股份有限公司 一种3-溴-5-氯苯酚的制备方法
PT2501698T (pt) 2009-11-18 2018-07-23 Nat Res Council Canada Monómeros fluorados, oligómeros e polímeros para utilização em dispositivos eletrónicos orgânicos
CN102146022B (zh) * 2010-02-05 2013-07-03 中国中化股份有限公司 3-氯-5-溴苯酚的制备方法
CN103025696B (zh) 2010-07-15 2015-08-12 阿尔比马尔公司 用于制备4-溴代-2-甲氧基苯甲醛的方法
BR112015005997A8 (pt) * 2012-09-26 2023-04-11 Merck Sharp & Dohme Composto
PE20151521A1 (es) 2012-12-20 2015-11-25 Inception 2 Inc Compuestos de triazolona y usos de los mismos
MX2016002795A (es) 2013-09-06 2016-05-26 Inception 2 Inc Compuestos de triazolona y usos de los mismos.
GB2598624A (en) * 2020-09-07 2022-03-09 Lorico Aurelio Use of triazole analogues for inhibition of a tripartite VOR protein complex in multicellular organisms

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274185A (en) 1963-10-08 1966-09-20 S E Massengill Company Phthalazine derivatives
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
JP2593084B2 (ja) 1986-12-19 1997-03-19 メレルダウファーマスーティカルズ インコーポレーテッド ５−アリールー３ｈ−１，２，４−トリアゾールー３−オン類の神経変性障害の処置への用途
US5436252A (en) 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
JP2542880B2 (ja) 1986-12-19 1996-10-09 メレルダウファーマスーティカルズ インコーポレーテッド ５−アリ―ル−３ｈ−１，２，４，−トリアゾ―ル−３−オン類の抗痙攣剤としての用途
US4826990A (en) 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5103014A (en) 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US4942236A (en) 1987-09-30 1990-07-17 American Home Products Corporation 2-aryl substituted pyridyl-containing phenyl sulfonamido compounds as antiallergic and antiinflammatory agents
US5331002A (en) 1990-04-19 1994-07-19 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
WO1997040017A2 (en) 1996-04-19 1997-10-30 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
US6367003B1 (en) * 1998-03-04 2002-04-02 Micron Technology, Inc. Digital signal processor having enhanced utilization of multiply accumulate (MAC) stage and method
IT1305313B1 (it) * 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
UA82048C2 (uk) * 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
WO2002040021A2 (en) * 2000-11-17 2002-05-23 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ

Also Published As

Publication number Publication date
AR050266A1 (es) 2006-10-11
TW200616979A (en) 2006-06-01
EP1773790A1 (en) 2007-04-18
RU2394028C2 (ru) 2010-07-10
BRPI0513858B1 (pt) 2020-11-10
IL180495A0 (en) 2007-06-03
CA2574308A1 (en) 2006-02-02
CN1993332A (zh) 2007-07-04
MX2007000788A (es) 2007-03-23
BRPI0513858B8 (pt) 2021-05-25
CA2574308C (en) 2014-03-25
EP1773790B1 (en) 2012-08-15
JP4675959B2 (ja) 2011-04-27
WO2006010545A1 (en) 2006-02-02
AU2005266530B2 (en) 2012-04-12
IL180495A (en) 2013-12-31
CN1993332B (zh) 2011-04-06
JP2008508211A (ja) 2008-03-21
US20060025462A1 (en) 2006-02-02
NO338376B1 (no) 2016-08-15
TWI299334B (en) 2008-08-01
NO20070258L (no) 2007-01-15
US7666891B2 (en) 2010-02-23
RU2007106928A (ru) 2008-09-10
SG148179A1 (en) 2008-12-31
ES2391461T3 (es) 2012-11-27
AU2005266530A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
BRPI0513858A (pt) compostos de benziltriazolona como inibidores não-nucleosìdeos da transcriptase reversa
EA200900066A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил) -d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
CY1117576T1 (el) Δινουκλεοτιδικα προφαρμακα
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
UA117800C2 (uk) Похідні урацилу або тиміну для лікування гепатиту с
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
BR112013028430A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
EA200970156A1 (ru) Пиридизиноновые производные
EA201170772A1 (ru) Органические соединения
ATE517882T1 (de) Chinolinderivate
BRPI0507198A (pt) derivados de bisariluréia
BRPI0818533B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BRPI0819328A8 (pt) Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
DE602007008616D1 (de) Verfahren zur herstellung von 4'-azidocytidinderivaten
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
BRPI0518096A (pt) composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos
BRPI0407591A (pt) inibidores de transcriptase reversa de não-nucleosìdeo
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BRPI0408767A (pt) inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv
BRPI0508102A (pt) inibidores de caspase e usos dos mesmos
BRPI0517032A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/07/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF